Article

Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future

2025-11-19

Abstract excerpt

Gastric cancer has historically relied on cytotoxic chemotherapy, yet its considerable mo lecular heterogeneity has limited therapeutic efficacy. The development of anti-body-mediated therapies has marked a new era in precision oncology, enabling selective targeting of biomarkers such as HER2, VEGFR2, PD-1/PD-L1, and CLDN18.2. This review summarizes the evolution of antibody-based strategies in gastric cancer, beg...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f17d02bf-d5c8-58aa-868d-3f3b764470ea
DOI: 10.20944/preprints202511.1385.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and FutureDOI 10.20944/preprints202511.1385.v1Read

Advanced gastric cancer: Current treatment landscape and future perspectives.Semantic proximity Read

Clinical impact of tumour biology in the management of gastroesophageal cancer.Semantic proximity Read

Current treatment and recent progress in gastric cancer.Semantic proximity Read

Current and emerging therapies in unresectable and recurrent gastric cancer.Semantic proximity Read

Identifying therapeutic targets in gastric cancer: the current status and future direction.Semantic proximity Read

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read

Treatment Selection for Patients with HER2-Negative Metastatic Gastric Cancer Expressing Claudin 18.2 and PD-L1Semantic proximity Read

Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.Semantic proximity Read

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read

Gastric cancer management: Kinases as a target therapySemantic proximity Read

First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-positive gastric cancer with sequential genomic profilingSemantic proximity Read